MIP-3α、SAA1、GSK-3β在急性冠脉综合征患者血清中的变化及其临床意义

承德医学院学报 ›› 2025, Vol. 42 ›› Issue (3): 200-204.

MIP-3α、SAA1、GSK-3β在急性冠脉综合征患者血清中的变化及其临床意义

李光华¹, 石晓宇², 刘洋²

1.河南宏力医院急诊科,河南新乡 453400;
2.鹤壁市人民医院急诊科,河南鹤壁 458000

收稿日期:2024-07-10 出版日期:2025-06-10 发布日期:2025-06-18

Changes and Clinical Significance of MIP-3α, SAA1, and GSK-3β in Serum of Patients with Acute Coronary Syndrome

LI Guang-hua¹, SHI Xiao-yu², LIU Yang²

1. Department of Emergency, Henan Hongli Hospital, Xinxiang, Henan, 453400, China;
2. Department of Emergency, Hebi People's Hospital, Hebi, Henan, 458000, China

Received:2024-07-10 Online:2025-06-10 Published:2025-06-18

摘要/Abstract

摘要： 目的分析急性冠脉综合征（ACS）患者血清巨噬细胞炎症蛋白3α（MIP-3α）、淀粉样蛋白A1（SAA1）、糖原合成酶激酶-3β（GSK-3β）水平变化及其临床意义。方法回顾性收集河南宏力医院2023年2月~2024年2月收治的162例ACS患者资料为研究对象,并且根据Gensini评分将患者按冠状动脉狭窄的程度分为重度组（n=50）、中度组（n=46）、轻度组（n=66）,另选取同期55例健康体检者为健康组;对比4组入院时血清MIP-3α、SAA1、GSK-3β水平,并进行相关性分析;对比不同预后患者入院时血清各指标水平,并分析对患者预后的预测价值。结果 4组入院时血清MIP-3α、SAA1、GSK-3β水平比较;重度组>中度组>轻度组>健康组（P<0.05）;入院时血清MIP-3α、SAA1、GSK-3β均与Gensini评分呈正相关（P<0.05）;预后不良患者入院时MIP-3α、SAA1、GSK-3β水平均高于预后良好患者（P<0.05）;入院时血清MIP-3α、SAA1、GSK-3β水平联合检测对预测患者发生预后不良的AUC为0.805,均高于各指标单独诊断（P<0.05）。结论 ACS患者血清MIP-3α、SAA1、GSK-3β水平升高,并与冠脉病变程度及预后有关,三者均可作为反应ACS病情严重程度的标志物,对预测患者预后具有重要价值。

关键词: MIP-3α, SAA1, GSK-3β, 急性冠脉综合征

Abstract: Objective To analyze the changes in serum levels of macrophage inflammatory protein 3α (MIP-3α), serum amyloid A1 protein (SAA1), and glycogen synthase kinase-3β (GSK-3β) in patients with acute coronary syndrome (ACS) and their clinical significance. Methods The data of 162 ACS patients admitted to Henan Hongli Hospital from February 2023 to February 2024 were retrospectively collected and served as the research subjects. Furthermore, based on the Gensini score, patients were categorized into severe (n=50), moderate (n=46), and mild (n=66) groups according to the degree of coronary artery stenosis. Additionally, 55 healthy individuals who underwent physical examinations during the same period were selected as the healthy group. The levels of serum MIP-3α, SAA1, and GSK-3β were compared among the four groups at admission, and correlation analysis was conducted. The levels of various serum indicators were compared among patients with different prognoses at admission, and their predictive value for patient prognosis was analyzed. Results Comparison of serum MIP-3α, SAA1, and GSK-3β levels at admission among four groups: severe group > moderate group > mild group > healthy group (P<0.05); serum MIP-3α, SAA1, and GSK-3β levels at admission were positively correlated with Gensini scores (P<0.05); patients with poor prognosis had higher levels of MIP-3α, SAA1, and GSK-3β at admission than those with good prognosis (P<0.05); the AUC for predicting poor prognosis in patients based on combined detection of serum MIP-3α, SAA1, and GSK-3β levels at admission was 0.805, which was higher than that based on individual diagnosis of each indicator (P<0.05). Conclusion Patients with ACS exhibit elevated levels of serum MIP-3α, SAA1, and GSK-3β, which are associated with the severity of coronary lesions and prognosis. All three markers can serve as indicators of the severity of ACS and are of significant value in predicting patient prognosis.

Key words: MIP-3α, SAA1, GSK-3β, Acute coronary syndrome

中图分类号:

R541.4

李光华, 石晓宇, 刘洋. MIP-3α、SAA1、GSK-3β在急性冠脉综合征患者血清中的变化及其临床意义[J]. 承德医学院学报, 2025, 42(3): 200-204.

LI Guang-hua, SHI Xiao-yu, LIU Yang. Changes and Clinical Significance of MIP-3α, SAA1, and GSK-3β in Serum of Patients with Acute Coronary Syndrome[J]. Journal of Chengde Medical University, 2025, 42(3): 200-204.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: http://tougao.cdmc.edu.cn:8088/CN/

http://tougao.cdmc.edu.cn:8088/CN/Y2025/V42/I3/200

参考文献

[1] 孟洁,苏立贞,晋婕. 急性冠脉综合征患者血清HMGB1、LP-PLA2、IMA的表达水平及其与预后的关系[J]. 海南医学,2023,34(11):1560-1564.
[2] 唐冬娟,江来,江叶. 血清miR-499与急性冠脉综合征患者冠状动脉病变严重程度的相关性分析[J]. 上海交通大学学报(医学版),2024,44(4):469-473.
[3] 肖立平,张利英,张云洁,等. 急性冠脉综合征患者血清NGAL、suPAR、sOSCAR表达水平及与预后的相关性[J]. 河北医药,2023,45(18):2817-2820.
[4] Yang ZY, Guo YH, Chen M, et al.Pleural cytokines MIF and MIP-3α as novel biomarkers for complicated parapneumonic effusions and empyema[J]. Sci Rep, 2021, 11(1): 1763.
[5] 贺永贵,李王芳,伊红丽,等. 黄芪甲苷抑制GSK-3β活性介导大鼠心肌缺血/再灌注损伤作用的线粒体机制研究[J]. 中国药理学通报,2014,30(3):402-406.
[6] 戴博,陈科新,王勇. STEMI患者血清SAA1、NOS和MDA水平变化与PCI术后发生心室重塑的关系[J]. 中国循证心血管医学杂志,2023,15(6):721-725.
[7] Licordari R, Costa F, Garcia-Ruiz V, et al.The Evolving Field of Acute Coronary Syndrome Management:A Critical Appraisal of the 2023 European Society of Cardiology Guidelines for the Management of Acute Coronary Syndrome[J]. J Clin Med, 2024, 13(7): 1885.
[8] 中华医学会心血管病学分会介入心脏病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,中华心血管病杂志编辑委员会. 中国经皮冠状动脉介入治疗指南(2016)[J]. 中华心血管病杂志,2016,44(5):382-400.
[9] 李妙男. 血浆N--乙酰--神经氨酸水平和急性冠脉综合征患者临床诊断、危险分层及临床预后之间的相关性研究[D]. 山东:山东大学,2021.
[10] 陈志清,李浪. GSK-3β调节心肌纤维化的研究进展[J]. 广西医科大学学报,2020,37(3):533-537.
[11] 陈儒,栾璐璐,李海岩,等. 急性冠状动脉综合征患者血清糖原合成酶激酶-3β和母亲DPP同源物4的表达及临床意义[J]. 中国医师进修杂志,2024,47(5):403-408.
[12] 和军辉,万大国,董静,等. 泛免疫炎症值、全身免疫炎症指数与急性冠脉综合征患者易损斑块的相关性研究[J]. 中国全科医学,2024,27(24):2976-2981.
[13] 刘天骄,张欣,王晓菲,等. 依洛尤单抗联合常规他汀与单纯他汀强化对急性冠脉综合征患者疗效及对血清HMGB1、SAA1、CCL19表达的影响[J]. 疑难病杂志,2023,22(4):361-366.
[14] 林先昌,卓剑,蔡强文. 血清淀粉样蛋白A1、脂蛋白结合指数预测急性冠脉综合征患者病情严重程度及预后的价值[J]. 标记免疫分析与临床,2021,28(4):651-655.
[15] 沈振丽,朱雪梅. 血清LBP、MIP-3α与急性冠脉综合征患者冠状动脉病变程度及预后的关系[J]. 中国循证心血管医学杂志,2023,15(6):726-729.